The aim of the present review is to define the proper management to prevent, detect early, and treat cardiotoxicity in patients with breast cancer due to anthracyclines and/or human epidermal growth factor receptor 2 inhibitors (HER2i). This evidence concerns the gene ERBB2 and breast cancer.